Investing in Eagle Pharmaceuticals, Inc. (EGRX)  ➔  Intrinsic value

Prev. close$43.62 
ModelValueUpside
Chepakovich$49.22+13%
Graham-Dodd$14.80-66%
Graham$51.90+19%
Previous Close$43.62  
Valuation MethodValuePotential 
Chepakovich Model$49.22+13%recalculate
Graham-Dodd$14.80-66%recalculate
Graham Formula$51.90+19%recalculate

Latest news

Company description

Eagle Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers Argatroban, an anti-coagulant thrombin inhibitor for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also includes EP-4104, a dantrolene sodium for exertional heat stroke, as well as to treat organophosphate exposure; EP-5101 (PEMFEXY) for lung cancer and mesothelioma; EGL-5385-C-1701 (fulvestrant) for breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has a strategic collaboration with Tyme Technologies, Inc. to advance oral SM-88 for the treatment of patients with cancer. Eagle Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Woodcliff Lake, New Jersey.